Modular Nanotechnologies for Cancer Drug Screening

用于癌症药物筛选的模块化纳米技术

• 批准号: 6333988
• 负责人: CYNTHIA C. BAMDAD
• 金额: $ 38.8万
• 依托单位: MINERVA BIOTECHNOLOGIES CORPORATION
• 依托单位国家: 美国
• 财政年份: 2000
• 资助国家: 美国
• 起止时间: 2000-01-01 至 2003-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6333988
• 关键词: angiogenesis inhibitors; biomedical equipment development; biomimetics; colorimetry; drug screening /evaluation; high throughput technology; nanotechnology; technology /technique development

DESCRIPTION: (provided by applicant) We propose to further develop, multiplex, and apply novel nanotechnologies, demonstrated in Phase I. These technologies will, for the first time, enable effective, high throughput drug screening that will identify novel compounds that block ligand-receptor interactions on the surface of live cells. We will target specific cell surface receptors that have been implicated in tumorigenesis, metastasis and angiogenesis. A second in vitro nano-based technology will be extended to screen for synthetic mimics of protein-based drugs, such as antibodies and natural products. These assays will be specifically developed to identify synthetic mimics of known angiogenesis inhibitors, for which large-scale production costs may be prohibitive. Large, chemically diverse drug libraries will be screened as a part of this project. PROPOSED COMMERCIAL APPLICATION: The technologies demonstrated in Phase I have significant commercial potential. One technology enables high throughput screening for a class of target receptors implicated in cancer that have heretofore been difficult to assay in a relevant way. The other technology offers a direct approach to identifying synthetic mimics of drugs that are too costly to produce in mass quantities. The technologies are modular and thus easily adapted to facilitate screening of a wide variety of targets without further modification to the platform technology. Both the technologies as well as any drug leads identified would be of extreme interest to pharmaceutical companies.

描述：（申请人提供） 我们建议进一步开发，多重和应用新颖的纳米技术， 这些技术将首次启用 有效的高通量药物筛查将鉴定出新的化合物 该阻断了活细胞表面上的配体 - 受体相互作用。我们将 与已与之相关的特定细胞表面受体 肿瘤发生，转移和血管生成。第二个基于纳米的体外 技术将扩展到筛选基于蛋白质的合成模仿 药物，例如抗体和天然产物。这些测定将是 专门为鉴定已知血管生成的合成模拟而开发 大规模生产成本的抑制剂可能会过高。大的， 化学多样的药物库将作为该项目的一部分进行筛选。 拟议的商业应用： 在第一阶段证明的技术具有巨大的商业潜力。 一 技术可以为一类涉及的目标受体进行高吞吐量筛查 在迄今难以以相关方式测定的癌症中。 另一个 技术提供了一种直接的方法来识别也是的合成模仿的药物 批量生产的昂贵。 这些技术是模块化的，因此很容易改编 促进筛选各种目标，而无需进一步修改 平台技术。 这些技术以及所确定的任何药物都将是 制药公司非常感兴趣。